Get the Stockscreener App
0.9915
4.66%
-0.0485
Oncolytics Biotech Inc stock is traded at $0.9915, with a volume of 782.98K.
It is down -4.66% in the last 24 hours and down -12.26% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.04
Open:
$1.05
24h Volume:
782.98K
Relative Volume:
0.76
Market Cap:
$99.51M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.7486
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-8.19%
1M Performance:
-12.26%
6M Performance:
+130.74%
1Y Performance:
-0.70%
1-Day Range:
$0.99
$1.0576
1-Week Range:
$0.99
$1.11
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9915 | 110.39M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech Reschedules Shareholder Meeting Amid SEC Delays - TipRanks
Oncolytics Biotech reschedules special meeting due to government shutdown By Investing.com - Investing.com Australia
Oncolytics Biotech reschedules special meeting due to government shutdown - Investing.com India
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders - Business Wire
Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 By Investing.com - Investing.com Australia
Can Oncolytics Biotech Inc. stock attract ESG capital inflowsWeekly Gains Report & Real-Time Volume Analysis - newser.com
Can Oncolytics Biotech Inc. stock sustain free cash flow growth2025 Bull vs Bear & Consistent Income Trade Recommendations - newser.com
FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst - MarketBeat
Oncolytics Biotech (TSX:ONC) Growth In Emerging Global Oncology Markets - Kalkine Media
Oncolytics Biotech (TSE:ONC) Advances Clinical Focus in Cancer Therapy - Kalkine Media
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - BioSpace
Can Oncolytics Biotech Inc. stock rebound after recent weaknessDollar Strength & Long-Term Growth Portfolio Plans - newser.com
What recovery options are there for Oncolytics Biotech Inc.Quarterly Trade Report & Expert Approved Momentum Ideas - newser.com
Will Oncolytics Biotech Inc. outperform the marketWeekly Stock Summary & Community Consensus Stock Picks - newser.com
Using data tools to time your Oncolytics Biotech Inc. exitTreasury Yields & Low Drawdown Trading Techniques - newser.com
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy - sharewise.com
Backtesting results for Oncolytics Biotech Inc. trading strategies2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech (ONCY) Advances with FDA-Approved Study Desig - GuruFocus
Oncolytics Biotech Reaches FDA Alignment on Phase 3 Pancreatic Cancer Trial Design - MarketScreener
Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026 - Investing.com India
Oncolytics, FDA agree on phase 3 trial design for elareorep in pancreatic cancer - Seeking Alpha
Oncolytics Biotech Inc. Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - MarketScreener
Oncolytics (ONCY) and FDA Align on Phase 3 Pelareorep Study Desi - GuruFocus
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial - TradingView
Oncolytics Biotech Aligns with FDA for Pivotal Pancreatic Cancer Study - TipRanks
Oncolytics Biotech aligns with FDA on pivotal study design for pelareorep in first-line pancreatic cancer - MarketScreener
Will Oncolytics Biotech Inc. stock keep outperforming rivalsWeekly Investment Summary & Fast Moving Trade Plans - newser.com
Using Ichimoku Cloud for Oncolytics Biotech Inc. technicalsDollar Strength & Growth Oriented Trade Recommendations - newser.com
Heatmap analysis for Oncolytics Biotech Inc. and competitors2025 Risk Factors & Technical Buy Zone Confirmations - newser.com
Analyzing Oncolytics Biotech Inc. with risk reward ratio chartsWeekly Gains Report & Community Verified Trade Alerts - newser.com
Why analysts remain bullish on Oncolytics Biotech Inc. stock2025 Earnings Surprises & Verified Entry Point Signals - newser.com
Oncolytics Biotech (NASDAQ:ONCY) Price Target Raised to $10.00 - MarketBeat
Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers - TipRanks
Oncolytics Biotech stock price target doubled to $10 by H.C. Wainwright - Investing.com South Africa
Oncolytics Biotech (ONCY) Price Target Raised by HC Wainwright | - GuruFocus
The 5-Minute Investor Podcast, Ep. 37: Cancer-fighting stocks | 2025-11-17 | Investing News - Stockhouse
Why Oncolytics Biotech Inc. is moving today2025 Geopolitical Influence & Low Risk High Win Rate Picks - newser.com
Visual trend scoring systems applied to Oncolytics Biotech Inc.Portfolio Performance Summary & AI Based Buy/Sell Signal Reports - newser.com
Is Oncolytics Biotech Inc a good long term investmentVolume Analysis Techniques & Capital Growth Strategies - earlytimes.in
What Analyst Ratings Reveal About Mafatlal Industries Limiteds Future ValueHigh Beta Stocks & Free Robust Financial Gains - earlytimes.in
How to interpret RSI for Oncolytics Biotech Inc. stockM&A Rumor & High Accuracy Swing Trade Signals - newser.com
Can you recover from losses in Oncolytics Biotech Inc.2025 Performance Recap & AI Powered Buy/Sell Recommendations - newser.com
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):